Elevated FAPI Activity in Ulcerative Fungal Esophagitis

Clinical Nuclear Medicine
|October 26, 2023
PubMed

Insights

Ulcerative fungal esophagitis can mimic esophageal cancer on imaging. Increased uptake of 18F-FDG and 68Ga-FAPI (fibroblast-activating protein inhibitor) may indicate this condition.

Area of Science:

  • Medical Imaging
  • Mycology
  • Gastroenterology

Background:

  • Esophageal masses often require differential diagnosis including malignancy and infection.
  • Positron emission tomography (PET) tracers like 18F-FDG are used to assess metabolic activity.
  • Novel tracers like 68Ga-FAPI target fibroblast activation, common in cancer and inflammation.

Observation:

  • A case presented with an ulcerative fungal esophagitis.
  • The condition showed elevated uptake of 18F-FDG on PET imaging.
  • Significantly, there was also increased uptake of 68Ga-FAPI in the affected esophagus.

Findings:

  • Ulcerative fungal esophagitis demonstrated increased radiotracer accumulation.
  • The pattern of uptake, particularly with 68Ga-FAPI, resembled that of esophageal cancer.
  • This highlights the potential for misdiagnosis based solely on imaging findings.

Implications:

  • Consider fungal esophagitis in the differential diagnosis of esophageal masses with increased 68Ga-FAPI uptake.
  • This finding may refine the interpretation of PET/CT scans in esophageal diseases.
  • Further research is needed to delineate imaging characteristics of fungal esophagitis versus malignancy.

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
117
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
517
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438